MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Olfaction analysis in spinocerebellar ataxia type 10 and type 3 comparing with healthy controls and PD

M. Moscovich, A. Moro, R. Munhoz, H.G. Teive, L.S. Moryiama (Curitiba, Brazil)

Meeting: 2016 International Congress

Abstract Number: 1032

Keywords: Ataxia: Clinical features, Cerebellum, Olfactory dysfunction, Spinocerebellar ataxia

Session Information

Date: Wednesday, June 22, 2016

Session Title: Ataxia

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To Analyse olfaction in spinocerebellar ataxia type 10 and type 3.

Background: The main clinical manifestations of spinocerebellar ataxias (SCA) result from the involvement of the cerebellum and its afferent and efferent connections. Previous studies have shown olfactory deficits in different forms of ataxia.

Methods: We recruted 30 patients with SCA3, 30 with SCA10, 30 with PD and 100 healthy controls. Sniffin Sticks (SS16) was used to assess the olfaction. Demographic data, neurological examination, SARA scale and MMSE were analyzed.

Results: From the SCA10 group 17 (56,7%) were female, the mean age was 48,5 ± 11,4 years and a total of 14 (46,7%) were smokers. Of the 30 patients with SCA3, 16 (53,3%) were women; the mean age was 51,3 ± 9,8 years and 10 (33,3%) were smokers. The group of healthy controls, 30 (68,2%) were women, mean age was 46,6 ± 11,1 years and 21 47,7%) were smokers. The PD group, were composed of 13 (43,3%) women, the mean age was 66,4 ± 8,8 years and only 2 (6,7%) were smokers. The mean disease duration of SCA10 patients was 14,2 ± 11 years and in patients with SCA3 was 11,3 ± 6. The mean SS16 score for the SCA10 group was 11,9 ± 2,9, and 12,3 ± 1,9 in the SCA3, the PD group mean SS16 score was 6,6 ± 2,8 and control group 12,1 ± 2,0. The SS16 score did not preset a significant olfactory deficits when compared to SCA10 with SCA3 or control group, however was a significant higher in ataxias than in DP group (p < 0.001). The number of repeat expansions was also analyzed in 17 SCA10 patients and 14 SCA3 patients. When analyzed the association between the number of repeat expansion and the SS16 score, this was not statistically significant p = 0,739 and p = 0,303 respectively. When performed the evaluation of the association between the SS16 score and the disease duration this also not found statistical significance. However the association between the score of SS16 and Mini Mental score was statistically significant in the control group (p = 0,007), SCA3 group (p = 0,005) and SCA10 group (p = 0,001).

Conclusions: This study confirms previous findings in ataxia hyposmia when compared with Parkinson’s disease. However association of the olfactory deficit with disease duration or repeat expansion was not found.

To cite this abstract in AMA style:

M. Moscovich, A. Moro, R. Munhoz, H.G. Teive, L.S. Moryiama. Olfaction analysis in spinocerebellar ataxia type 10 and type 3 comparing with healthy controls and PD [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/olfaction-analysis-in-spinocerebellar-ataxia-type-10-and-type-3-comparing-with-healthy-controls-and-pd/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/olfaction-analysis-in-spinocerebellar-ataxia-type-10-and-type-3-comparing-with-healthy-controls-and-pd/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley